Novo Nordisk launches Wegovy pill in UAE in first global rollout outside US

The move signals a major expansion in access to next-generation weight-loss therapies

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors

Eli lilly goes all-in on vaccines with $3b+ triple acquisition push into infectious disease prevention

Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.

Sun's cancer drug shines delivering 50% response rate with long-lasting tumor control

These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC

Genethon and Ampersand team up to engineer next-gen gene therapy vectors with precision

AAV vectors are widely used in gene therapy for their strong therapeutic potential

Pfizer advances next-gen pneumococcal vaccine after strong Phase 2 infant data

Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma